Investigating the The Effect Of Evening Primrose On Blood Sugar And Lipid Profile In Pre-Diabetic Menopausal Women

Investigating the The Effect Of Evening Primrose On Blood Sugar And Lipid Profile In Pre-Diabetic Menopausal Women Referred To Rafsanjan Comprehensive Health Services Centers In 1397

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181210041911N2

Enrollment

Registered

2019-08-26

Start date

2019-03-11

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood sugar and lipids in pre-diabetic menopausal women. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: After measuring the levels of FBS, HbA1C, HDL, LDL, TG and cholesterol, the participants consumed 2 of Evening Primrose capsules for 3 months ( At night and in the

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: written consent of the company in the study Pre-diabetic women (fasting blood glucose 125-100 mg / dl) Non-use of alcohol, tobacco and narcotics . Lack of HRT at present Non-use of supplementary extract of Maghrib flower Women who have been at least 12 months since their last menstruation Lack of chronic mental illness No use of blood glucose suppressants

Exclusion criteria

Exclusion criteria: Need to use insulin No proper use of the capsule Sensitization to the capsule Mistake in the dosage of medication for 2 consecutive days Unwillingness to continue participating in the study at any time of the research

Design outcomes

Primary

Measure	Time frame
Percentage of people with abnormal HDL. Timepoint: Measurement of before intervention and 3 months after intervention. Method of measurement: Laboratory values.;Percentage of people with abnormal LDL. Timepoint: Measurement of before intervention and 3 months after intervention. Method of measurement: Laboratory values.;Percentage of people with abnormal TG. Timepoint: Measurement of before intervention and 3 months after intervention. Method of measurement: Laboratory values.;Percentage of people with abnormal Cholesterol. Timepoint: Measurement of before intervention and 3 months after intervention. Method of measurement: Laboratory values.	—

Measure

Time frame

Percentage of people with abnormal HDL. Timepoint: Measurement of before intervention and 3 months after intervention. Method of measurement: Laboratory values.;Percentage of people with abnormal LDL. Timepoint: Measurement of before intervention and 3 months after intervention. Method of measurement: Laboratory values.;Percentage of people with abnormal TG. Timepoint: Measurement of before intervention and 3 months after intervention. Method of measurement: Laboratory values.;Percentage of people with abnormal Cholesterol. Timepoint: Measurement of before intervention and 3 months after intervention. Method of measurement: Laboratory values.

—

Secondary

Measure	Time frame
FBS levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.;HDL levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.;LDL levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.;TG levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.;Cholesterol levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.	—

Measure

Time frame

FBS levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.;HDL levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.;LDL levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.;TG levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.;Cholesterol levels. Timepoint: 3 month after intervention. Method of measurement: Laboratory values.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAsma Absalan

Rafsanjan University of Medical Sciences

asma.absalan.a@gmail.com+98 34 3425 5900

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026